Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland, developing solutions to improve the treatment and prognosis for dialysis patients. Extra-corporeal treatments like dialysis, cardiopulmonary bypass, and ECMO involve the circulation of the patient's blood supply through a machine. The patient's immune system treats the machine as a large, unwanted foreign body; the resulting inflammatory response contributes to a range of serious complications that drive morbidity and mortality and reduce the quality of life.
Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications. With its proprietary H-Guard™ technology, Invizius is addressing the side effects of hemodialysis to help patients feel better, and suffer fewer cardiovascular complications.
Total Funding: £9.2 M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2C
Company Size: 1 to 25
Founded: 2018
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Invizius
